Method for PR-39 peptide mediated selective inhibition of...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S002600, C514S015800, C435S001100, C435S004000, C435S325000

Reexamination Certificate

active

10391155

ABSTRACT:
The present invention provides both a method and means for regulating IκBα degradation, NFκB activity, and NFκB-dependent gene expression within living cells, tissues, and organs in-situ. The selective regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for interaction with such IκBα and proteasomes as are present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with IκBα is a selective alteration in the intracellular proteolytic activity of proteasomes, which in turn, causes a reduction of IκBα, a decrease of NFκB activity, and a down-regulation of NFκB-dependent gene expression.

REFERENCES:
Anderson. Nature vol. 392. 1998. pp. 25-30.
Verma et al. Nature vol. 389. 1997. pp. 239-242.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for PR-39 peptide mediated selective inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for PR-39 peptide mediated selective inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for PR-39 peptide mediated selective inhibition of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3776476

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.